Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy involving the spleen,
bone marrow, and frequently the blood. SMZL lymphomagenesis involves antigen and/or …

Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma
characterized by massive splenomegaly, moderate lymphocytosis with or without villous …

Treatment of splenic marginal zone lymphoma (SMZL) is not standardized due to the lack of
prospective randomized trials. 1-13 After our initial 2007 paper, we now present updated …

Splenic marginal zone lymphoma (SMZL) accounts for less than 2% of all non‐Hodgkin
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from …

Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are
derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic …

Marginal zone lymphomas (MZL) represent around 8% of all non-Hodgkin lymphomas.
During the last decades a number of studies have addressed the mechanisms underlying …

Splenic B-cell lymphomas are a heterogeneous group of diseases comprising several
entities that exhibit overlapping features. Diagnosis of these lymphomas has been reliant on …

Splenic marginal zone lymphoma (SMZL) is a distinct lymphoma entity characterized by an
indolent clinical course and prolonged survival. Treatment is not standardized, since there …

The management of marginal zone lymphoma (MZL), an indolent B-cell non-Hodgkin
lymphoma, requires a personalized and adaptive approach due to its clinical and prognostic …

Background SMZL is a relatively rare low grade B-cell lymphoma, characterized usually by
an indolent clinical behavior. Since there is no prospective randomized trials to establish the …